Aims: Identifying the factors that contribute to chronicity in inflamed colitic tissue is not 24 trivial. However, in mouse models of colitis, we can investigate at preclinical timepoints. We 25 sought to validate murine Trichuris muris infection as a model for identification of factors 26 that promote development of chronic colitis. 27
Introduction 47
Inflammatory bowel diseases (IBD) are a group of intestinal immune disorders, including 48
Crohn's disease (CD) and ulcerative colitis (UC), that cause chronic inflammation in the gut 49 [1] . The cause of IBD is currently not known, but dysregulation of intestinal immunity, 50 microbial dysbiosis, genetics and environmental factors contribute to disease onset. 51
Unpredictable cycles of remission and relapse require careful monitoring and the long-term 52 damage from inflammation often warrants potent immunomodulatory therapy or surgical 53 intervention [2] . 54
It is impossible to reliably predict onset, relapse or remission of IBD [3] and currently, only 55 animal models provide a means of studying the perturbations in the gut that precede colitis. 56
Infecting susceptible mouse strains with the enteric nematode parasite Trichuris muris 57 closely parallels human Crohn's disease in both the pathological and transcriptional changes 58 induced [4] and has been established as a model for the study of the initiation of immune 59 responses in the colon [5] . T. muris resistant BALB/c and C57BL6 mice mount an early 60 immune response against the worms within 24 hours of infection, with large numbers of 61 dendritic cells (DCs) migrating to the lamina propria, whereas AKR mice or C57BL/6 mice 62 with a low dose infection mount a delayed immune response, resulting in chronic intestinal 63 inflammation and a failure to expel the worms [5, 6] . Both susceptible and resistant strains 64
show mild signs of inflammation within 24 hours. However, inflammation in resistant mice is 65 controlled and ultimately resolves, whereas susceptible strains go on to develop clinical 66 colitis in the subsequent weeks post infection. 67
Exploiting these early differences in the host immune response to T. muris infection 68 experimentally may provide information on the factors that promote the onset of chronic, 69 rather than resolving, inflammation in the gut [7] . Early factors are impossible to distinguish from the inflammatory milieu present in IBD patients at the point of diagnosis as chronic 71 inflammation is already well established. Identification and validation of early changes 72 during chronic colitis onset in mice could provide a useful pipeline for developing diagnostic 73 and disease-management biomarkers or therapeutic targets in human colitis. 74
In this study, we carried out a T. muris infection study, investigating preclinical 75 transcriptional changes 24 hours post infection (PI). We identified the receptor for advanced 76 glycation end-products (Rage) as highly upregulated in mice susceptible to T. muris 77 infection. We further investigated the presence of RAGE and related ligands in colitic mice 78 and carried out a translational validation study investigating the presence of soluble RAGE 79 (sRAGE) in the faeces of IBD patients and healthy controls. 80 81
Materials and methods 82
Mice 83
All animal procedures used in this project were carried out in accordance with the UK 84 Animals (Scientific Procedures) Act, 1986. For T. muris infection experiments, 6-8 week old 85 male BALB/c and AKR mice were used (Harlan UK, Bicester, UK). Mice were housed in 86 individually ventilated cages with nesting material and were maintained under constant 12h 87 light-dark cycle at 21-23 °C with free access to water and standard chow (Beekay Rat and 88
Mouse Diet, Bantin & Kingham, Hull, UK). Euthanasia was carried out by schedule 1 89 procedure of CO 2 asphyxiation followed by cervical dislocation or exsanguination. 3-6 mice 90 were used per strain, per time point studied. 91
Parasites and infection 92
Professor Kathryn Else, The University of Manchester, kindly provided eggs of T. muris 93 Edinburgh (E) isolate for use in all infection studies. Egg infectivity and maintenance of 94 parasite stocks were carried as described by Wakelin, 1967 [8] . Experimental mice were 95 infected with 200 embryonated eggs in 200 μl of ultra-pure distilled water via oral gavage. 96
Worm burden was assessed at day 21 PI. Caecum and proximal colon were harvested at 97 autopsy to determine parasite clearance of each mouse at the end of each experiment as 98 described by Else et al., 1990 [9] . 99
Human samples 100
Prior to the commencement of the clinical study, NHS ethics approval was obtained from 101 were recruited in accordance with the University ethics committee and the Human Tissue Act 2004. Faecal samples were taken from healthy controls (n=10) with no prior history of 106 IBD or gut problems, or patients (n=31) with suspected IBD or clinically confirmed IBD. All 107 patient samples were taken via outpatient clinics, returned by patients as part of standard 108 clinical practice to be assessed for Faecal Calprotectin (FCP). Colonoscopy/biopsy were 109 undertaken in those with elevated FCP. Of the patients, 6 patients had IBD excluded, mainly 110 leading to a clinical diagnosis of irritable bowel syndrome (IBS), 19 known IBD patients were 111 in remission at the of time testing (10 ulcerative colitis and 9 Crohn's disease) and 6 patients 112 had active IBD (n=5 CD, n=1 UC) at the time of testing. 113
Statistics and analysis 114
Where statistics are quoted, experimental groups were compared using linear regression, 115
Mann-Whitney U test or two-way analysis of variance (ANOVA) test followed by Sidak's post 116 hoc multiple comparisons test, where appropriate. P values <0.05 were considered 117 significant. Data are presented as mean ± SEM unless otherwise stated. Statistical analyses 118 were carried out using GraphPad Prism 7 (GraphPad Software, La Jolla, California, USA; 119 www.graphpad.com). 120
Results 121

Early immune response informs resistance to T. muris-induced colitis 122
Following challenge with Trichuris muris, as expected BALB/c mice expelled most or all of 123 the worms by 21 days PI, whereas AKR mice were unable to expel all worms and remained 124 infected with a significantly higher worm burden (P=0.016, Mann-Whitney U test) ( Figure  125 1A). Colitis scoring revealed increased histological changes associated with inflammation in 126 both AKR and BALB/c mice after infection ( Figure 1B ). These changes included influx of 127 immune cells, presence of immune cells in the submucosa, crypt hyperplasia and goblet cell 128 loss. In agreement with previous data, the colitis scores in BALB/c mice peaked at 21 days PI 129 and had begun to return to normal by 31 days PI. As expected, colitis scores in AKR mice 130 rose after infection and peaked at 31 days PI where the colitis score was significantly greater 131 than that of the BALB/c mice (P=0.046, ANOVA; Figure 1B ). Representative images of 132 haematoxylin and eosin stained proximal colon sections in naïve mice and at 31 days PI are 133 shown in Figure 1C . Collectively, these results reproduce previously published research in 134 the AKR/BALB/c infection model [4] , where BALB/c mice initiate an acute, resolving 135 inflammation after T. muris challenge and AKR mice show delayed immune response that 136 results in a chronic inflammatory phenotype due to a failure to expel worms. 137
We investigated immune cell recruitment to the colonic lamina propria by flow cytometry at 138 1, 7, 14, 21 and 31 days PI. BALB/c mice had an acute resolving response whereas AKR mice 139 developed a chronic inflammatory response. At 24 hours PI BALB/c mice responded rapidly 140 to T. muris challenge, with an early increase in the proportions of DCs, macrophages and 141 neutrophils (P<0.05, ANOVA) in colonic lamina propria tissues and mesenteric lymph nodes 142 compared to naïve mice ( Figure 1D and 1E, Supplementary data). BALB/c and AKR had 143 different responses to infection, with BALB/c tending to have greater recruitment of innate immune cells at D1 compared with susceptible AKR mice. This trend for a greater early 145 magnitude of response in the BALB/c compared with AKR was also seen at D7, D14 and D21 146 post-infection with the greatest differences between the immune response of BALB/c mice 147 to AKR at D14 PI ( Figure 1B, Supplementary data) . However, by D31, proportions of 148 macrophages (P<0.001), inflammatory monocytes (P<0.01) and neutrophils (P<0.001), were 149 all significantly greater in AKR mice, whereas the proportions of these cell types returned 150 near to baseline levels in BALB/c mice ( Figure 1D -G). The increase in immune cells observed 151 in AKR mice at D31 corresponded with the peak colitis score, and likewise the reduction in 152 immune cells in BALB/c mice at D31 was paralleled with a reduction in colitis score ( Figure  153 1B). Collectively this work indicated an altered dynamic of immune response in resistant 154 versus susceptible mice, therefore we explored the early transcriptome in order to 155 understand changes present between colitis-susceptible and colitis-resistant mice. 156
Transcriptional changes induced by T. muris infection identified at 24 hours post infection 157
Transcriptional changes in the proximal colon (the principal site of T. muris infection) were 158 investigated at 24 hours post-infection via microarray, prior to the establishment of overt 159 signs of inflammation. Genes with the largest differential expression at 24 hours post were 160 calculated ( Figure 2A ). Of the 77 probe sets that were significantly upregulated in AKR mice 161 and downregulated in BALB/c mice (1-IPPLR <0.05), 65 were successfully matched to gene 162 IDs in DAVID. The gene upregulated in colitis-susceptible AKR mice with the largest 163 differential expression compared to BALB/c mice was the receptor for advanced glycation 164 end-products (Rage) (Log2 fold change = 2.0718; 1-IPPLR = 0.003) ( Figure 2B ; Supplementary 165 data). Upregulation of Rage in susceptible mice was confirmed by qPCR of proximal colon at 166 24 hours PI in an independent experiment (P<0.001, Mann-Whitney U test, Figure 2C ). 167 Differential expression of transcription factors was analysed using TIGERi for MATLAB [10] . 168
The most notable change in transcription factor gene expression was the downregulation of 169
FoxO4 (Forkhead box O4) following T. muris infection in AKR mice (Supplementary data). 170
FOXO4 occurs downstream of the RAGE activation signalling cascade and serves to inhibit 171 DNA binding and transcriptional activity of NF-κB (nuclear factor kappa-B), preventing 172 inflammation [11] . FoxO4 is also downregulated in the colonic epithelial cells of IBD patients 173 [11] . The upregulation of proinflammatory Rage and downregulation of anti-inflammatory 174
FoxO4 from the RAGE signalling pathway provide compelling evidence for the relevance of 175 RAGE activation in colitis susceptibility in AKR mice during T. muris infection. 176
Identifying the cellular source of RAGE 177
Over 90% of CD326 + (EpCAM) epithelial cells expressed RAGE ( Figure 3A ) and they fell into 178 two distinct groups, expressing either low (RAGE lo ) or high (RAGE hi ) levels of RAGE. In naïve 179 mice, the total proportion of CD326 + epithelial cells that expressed RAGE was significantly 180 higher in colitis-susceptible AKR mice (P<0.01, ANOVA). The proportion of RAGE lo to RAGE hi 181 cells was similar in both naïve AKR and BALB/c mice, but there was significant drop in the 182 proportion of RAGE hi epithelial cells observed 2 and 7 days PI (P<0.0001, ANOVA), in both 183 AKR and BALB/c mice ( Figure 3B ). 184
Immunohistochemistry was used to confirm expression of RAGE in tissue ( Figure 3C ). Akin to 185 the flow cytometry data, we saw high expression of RAGE throughout the colonic 186 epithelium. Concurring with the flow cytometry data, there was only minimal fluorescence 187 seen in the immune lamina propria cells indicating that epithelial cells indeed express 188 greater amounts of membrane-bound RAGE than immune cells. This data suggest that the 189 epithelial cells are likely to be the source of the observed increase in Rage mRNA. There was 190 a reduction in intensity of RAGE staining at 7 days PI by immunohistochemistry ( Figure 3C Faecal sRAGE in the BALB/c mice increases relative to colitis scores (R 2 =0.99). However, 209 sRAGE levels in susceptible mice did not change during the course of infection relative to 210 increasing colitis scores from D0 to D21 post-infection (serum R 2 =0.99, faecal R 2 =0.73). 211
We then investigated levels of the RAGE ligand S100A8 (one part of the heterodimeric 212 calprotectin protein, currently used as a clinical biomarker for IBD) in serum and faeces as 213 an indicator of whether sRAGE might be quenching the proinflammatory effects of 214 circulating RAGE ligands by acting as a decoy receptor. Serum and faecal S100A8 did increase slightly during the course of infection in both AKR and BALB/c mice, but no 216 statistical differences were observed between the two strains and there was high variability 217 between mice. At 21 days PI BALB/c mice had greater levels of serum S100A8 than AKR mice 218 (not significant, ANOVA; Supplementary data). Faecal S100A8 remained broadly similar in 219 naïve and T. muris infected mice of both AKR and BALB/c strains. As with serum S100A8, 220 faecal S100A8 was slightly raised in BALB/c mice at 21 days PI compared to AKR mice but 221 this was not significant (ANOVA; (Supplementary data) ). In addition to being highly variable, 222 S100A8 correlated poorly with colitis scores (Supplementary data). 223
sRAGE is differentially expressed in IBD 224
As the differences in sRAGE were most apparent and consistent in faeces we focused on 225 analysis of faecal specimens from healthy volunteers and patients with IBD or suspected 226 IBD. sRAGE was not detected in the faecal samples of healthy volunteers. In contrast, s-227 RAGE was detectable in the patient cohort ( Figure 4A ). The highest levels of sRAGE were 228 seen in patients with IBD excluded (largely IBS ascribed) and IBD in remission, although 229 remission patients were more variable. Patients with active IBD characterised by severe 230 inflammation had low levels of sRAGE and increased calprotectin. 231
We then transformed the faecal RAGE and calprotectin ELISA data into present (1) or absent 232 (0), where protein is scored as present if ≥ 3*SD above baseline. When patient data was 233 stratified into groups (active IBD, IBD in remission, IBD excluded (IBS) and healthy controls) 234 the ratio of RAGE to calprotectin clearly identified healthy controls (0, 0) and active IBD (0, 235 1) from IBS and IBD in remission ( Figure 4B ). In healthy individuals, we saw no sRAGE or 236 calprotectin signal in any subject. In active IBD we had a consistent pattern of Calprotectin 237 present, but no sRAGE. For patients whose disease is resolving we saw a more complicated 238 picture, where we had a subset of patients undergoing routine test that were expressing 239 both sRAGE and Calprotectin. 240
Discussion 241
Animal models are crucial for examining the causative events that lead to diseases such as 242 chronic colitis. Genetic factors influence the likelihood of developing colitis, but it is 243 impossible to continually monitor individuals with potential genetically susceptibility in 244 order to identify the pathways that drive the development of chronic intestinal 245 inflammation. Models that accurately simulate preclinical changes in the gut allow us to 246 interrogate the pathways leading to chronic colitis, prior to the development of the complex 247 inflammatory environment when disease is established. Levison et al. [14] have previously 248 shown that T. muris infection in AKR mice causes colitis that correlates phenotypically and 249 transcriptionally with the profile of human CD. Here, we provide novel evidence reinforcing 250 the use of the T. muris infection as a model for the discovery of preclinical intestinal 251 inflammation markers that translate into human IBD patients. 252
In line with previous T. muris infection studies, we observed altered dynamics of the 253 immune response between colitis resistant versus susceptible mice, characterised by an 254 early influx of DCs [5] . We then identified upregulation of Rage as a potential indicator of 255 colitis susceptibility in mice. RAGE activity has already been linked to active IBD [15] as well 256 as other inflammatory diseases including diabetes, Alzheimer's, airway inflammation, cancer 257 and haemorrhagic shock [16] . Additionally, several RAGE ligands have been identified as 258 associated with the inflammation in IBD, including calprotectin, ]. Thus, our data from the mouse model shows a clear link to known pathology in IBD. It is 260 important to validate results from mouse model to human disease and therefore we 261 conducted a small validation study to assess faecal sRAGE. Faecal sRAGE was readily 262 detected in patient's faecal samples. Akin to the mouse data we saw lower sRAGE in 263 patients with active chronic inflammation. Surprisingly, symptomatic patients with IBD excluded on a basis of normal FCP and/or colonoscopy had higher levels of sRAGE than 265 healthy volunteers. Largely, IBS was clinically ascribed but that was not based on formal 266 diagnostic criteria, and other diagnoses such as bile acid diarrhoea or microscopic colitis 267
were not formally excluded. The sample size was small and more prospective studies are 268 needed to confirm this preliminary observation. Patients whose IBD was reported to be in 269 remission had variable levels of sRAGE. It is tempting to speculate that lower levels of sRAGE 270 are associated with a risk of subsequent flare of inflammation but as we only had single 271 samples from the patients, we cannot assess this, however it would be interesting to track 272 sRAGE over time in a prospective study of patients with IBD. 273 RAGE has been described on several immune cells with, for example, neutrophils identified 274 as expressing large amounts of RAGE [20] . Our flow cytometry and immunohistochemistry 275 analysis of RAGE expression in multiple cell types present in and around the lamina propria 276 and crypts of the colon, however, did not suggest that immune cells were the main sources 277 of cellular RAGE. Our data in fact showed that a major cellular source of RAGE in the gut 278 were the gut epithelial cells. Previous studies have shown that epithelial cells not only 279 express RAGE, but also upregulate RAGE expression during colonic inflammation [15] . 280
Changes we observed in the levels of RAGE expression suggest that it is the epithelial cell 281 response to T. muris infection that informs subsequent susceptibility to chronic 282 inflammation. The reduction in the amount of RAGE present at the cell membrane we saw 283 by flow cytometry and by immunohistochemistry immediately following T. muris infection 284 could be caused by either internalisation of activated RAGE-ligand complexes or ADAM10-285 mediated shedding to produce sRAGE [21, 22] . Splice variants of Rage may also result in a 286 truncated RAGE molecule or a modified and actively secreted decoy receptor [23, 24] the lymph nodes [15, 25] . However, whether the upregulation of Rage is crucial to facilitate 297 the early DC migration in the T. muris model remains unclear. While we observed 298 differences in DC migration as early as day 1 PI, we saw no differences between cell surface 299 RAGE expression between AKR and BALB/c mice that might account for the altered 300 dynamics of DC recruitment. Similarly, RAGE has been linked to neutrophil recruitment but 301 we only observed modest neutrophil infiltration in the first 24 hours PI and no difference 302 between colitis-susceptible or colitis-resistant mice. Despite minimal differences in immune 303 cell presence during the early stages of T. muris infection, prolonged activation of RAGE 304 results in activation of inflammatory signalling molecules including NF-κB and MAP kinases 305 [16] . Consequently, an environment where RAGE ligands such as HMGB1, and S100 proteins 306 are continually present results in perpetual NF-κB activation and subsequent chronic 307 inflammatory conditions. 308
We observed striking differences in the levels of faecal and systemic sRAGE between colitis-309 resistant and susceptible mice, with BALB/c mice rapidly producing sRAGE in response to T. 310 muris infection. sRAGE effectively acts as a decoy receptor for RAGE as it can still bind to the 311 same damage induced ligands as membrane bound RAGE but, as it lacks a cytoplasmic tail, it cannot initiate the pro-inflammatory signalling cascade [26] . Thus, higher levels of sRAGE 313 might be expected to block inflammation and indeed reduced levels of sRAGE have been 314 found in mice with chronic inflammation as well as patients suffering from chronic 315 inflammatory diseases [27] . The reduction in epithelial RAGE expression followed by 316 increases in circulating sRAGE in colitis-resistant mice suggests shedding of RAGE to form 317 sRAGE as a protective feedback process against the development of chronic inflammation. 318
Colitis-susceptible AKR mice show the same reduction in epithelial RAGE expression but did 319 not produce sRAGE in the same quantities, suggesting internalisation and activation of RAGE 320 and initiation of subsequent proinflammatory pathways after T. muris infection. Indeed, it is 321 known that T. muris excretory/secretory (E/S) products induce NF-κB signalling in colonic 322 epithelial cells shortly after infection and the susceptible immune response to T. muris is 323 associated with expression of the T helper (T H ) 1 cytokines interferon (IFN)-γ, tumour 324 necrosis factor (TNF)-α and IL-12 [28] . This response parallels the cytokines expressed after 325 RAGE activation, which include T H 1 and T H 17 cytokines TNF-α, IL-1α, IL-6, . 326 Diagnosis of IBD usually involves an assessment of clinical history and physical examination, 327 with endoscopy and histology considered to be the gold standard tools [29] . Accurately 328 assessing disease activity remains dependent on colonoscopy and/or small bowel imaging. 329
The invasiveness of current diagnostic methods is not ideal and recent work has aimed to 330 identify serum or faecal biomarkers that can reliably identify active disease [30] . The 331 number of potential IBD biomarkers is high, but there remains a lack of reliable and 332 reproducible biomarkers for use in clinical practice [31] . Efficacy of current therapies is also 333 variable, with risks of sometimes serious side effects, especially infection meaning there is Figure 4 
